Breaking News This AM - 22nd Century (Nasdaq: XXII) Regains Compliance with Nasdaq Stockholders' Equity Requirement

Breaking News This AM - 22nd Century (Nasdaq: XXII) Regains Compliance with Nasdaq Stockholders' Equity Requirement  Greetings FDR Subscribers, Mocksville, North Carolina--(Newsfile Corp. - October 8, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it has received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule").  This confirmation follows the Company's successful efforts to improve its balance sheet and liquidity by completing new equity offerings, while reducing outstanding liabilities and debt through various forms of settlement with creditors. As a result, the Company now meets Nasdaq's stockholders' equity minimum requirement of at least $2.5 million.  Larry Firestone, Chief Executive Officer said, "We are pleased to receive Nasdaq's notification confirming 22nd Century's regained compliance with the minimum stockholders' equity requirement. Over the past two quarters, we have made significant strides in improving our balance sheet and expanding our business. During this period, we have raised $11.6 million of equity proceeds and de-levered our balance sheet, among other activities, to reach the equity minimum of $2.5 million. We remain committed to ensuring our listing compliance and creating long-term shareholder value." 22nd Century Group (NASDAQ: XXII) stock presented a compelling investment proposition when we first featured it on September 23rd. As expected, investors seizing that opportunity were rewarded, with the stock appreciating over 17% intraday and even higher on the next. Moreover, with ample liquidity, evidenced by volume surpassing two million shares on each day noted, investors should have easily been able to book gains if they took a short-term trader's approach to investing. Those that did, congrats on a great trade. But we know that not all FDR subscribers are short-term momentum traders. That's why we feature companies that have the fundamentals to support a long-term strategy to deliver sustained upside movement. In XXII's case, it reacted quickly, consolidated, and then pulled back to its $0.18 price tag yesterday. That makes no sense. Supported by a couple of updates, XXII is a stronger company now than when we featured it in September. Since our initial update, XXII has published two press releases showing how its industry-changing VLN® (Very Low Nicotine) cigarettes could be the best-positioned product to seize a sizable share of a market targeting customers wanting all the pleasure of smoking but without the full measure of nicotine. The product is more than innovative; it serves a harm-reduction market that is growing in popularity. Serving the harm-reduction category boom... The appealing part of that category to consumers is that the products, like XXII's VLN®, don't deprive users of the satisfaction expected. In this case, XXII's VLN® cigarettes contain 95% less nicotine than traditional nicotine delivery products and are designed to help smokers reduce their nicotine intake without sacrificing the smoking experience they enjoy. While that's great for users, XXII also presents an excellent opportunity for investors. Here's why. 22nd Century's VLN® is the only FDA-approved cigarette that can be marketed as a Modified Risk Tobacco Product (MRTP). That distinction allows them to sell its product as one that "Helps You Smoke Less®," which resonates with smokers who aren't ready to quit but want to manage their nicotine consumption. The company is capitalizing on that designation. On September 25th, XXII announced a commitment from an existing customer to supply their filtered cigar products. As part of this deal, 22nd Century Group will assume production of all the customer's filtered cigar products using an in-house predicate blend. Initial shipments are expected in the fourth quarter of 2024, with volumes anticipated to be 200,000 cartons or more annually. Earlier this year, XXII signed an agreement with the same customer for its export conventional cigarette products business. That deal could add 20% to the overall contract manufacturing business volumes, which the company said should start to ramp up this year. Also in September, XXII announced an agreement to supply its Moonlight branded cigarettes to the Southeast Asian market, a deal that could grow its manufacturing volumes by more than 30% over the next 15 months. These updates add to others that show XXII is expanding its market presence in key markets. As importantly, with the company well-positioned to generate solid cash flows, its target of being cash flow positive by early 2025 is in the crosshairs. Products are available in thousands of retail locations... That mission is well underway. Currently, VLN® products are available in over 5,000 stores across 26 U.S. states. While impressive, XXII's ambitious plans include getting its products into at least 270,000 retail outlets nationwide. That kind of growth needs supporting infrastructure, which XXII has. In its company presentation, XXII noted its stockpile of low-nicotine tobacco ready and manufacturing capacity that could generate up to $85 million in revenue. More could follow. XXII said it plans to extend its VLN® brand with new "flanker" products, much like Coca-Cola extended its product line with Diet Coke, and Heineken introduced a zero-alcohol version of its beer. These new products would diversify the company's product portfolio while strengthening its brand and leadership positions in the reduced-nicotine category. Additionally, if XXII stays on its business course and meets expectations, the result could be XXII ushering in an entirely new product category within the tobacco industry, similar to how light beer offered a lower-calorie alternative for beer drinkers, and decaf coffee gave caffeine lovers a choice. FDR subscribers- it's easy to appreciate XXII for the products it sells. After all, they are well-designed and serve a potentially lucrative market. However, we aren't featuring XXII for that reason. FDR is all about introducing innovative companies that also present attractive investment opportunities. We did that with this company in September. The value proposition looks even more significant after a pullback in price despite publishing value-driving updates. A value proposition exposed... That assumption is based on several things. Foremost, XXII's VLN® cigarettes, as a breakthrough harm-reduction product, have the potential and early-mover advantage to disrupt the tobacco industry, similar to how decaf coffee and light beer revolutionized their respective markets. Add to that potential the FDA's MRTP designation, and XXII looks competitively better positioned than any other company to develop this market. In other words, XXII's achievements don't look to be fairly valued at current prices. Considering they are fundamentally stronger than at higher share prices, are advancing a robust product pipeline, are increasing manufacturing volumes, and are expanding into new global markets, an evidence-based case for XXII stock to move appreciably higher is well supported. Like last month, short-term and momentum investors could be rewarded. However, other than normal market fluctuations, XXII stock may do much better during a longer-term horizon into 2025. If objectives are met, prices may be more fairly represented in dollars, not cents. To Your Trading Success, Michael Reece Editor, Financial Driven Research Sources: [( [( [( [( [( [( [( [( [( [( [( [( [( © 2024 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates have been compensated twenty thousand USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc]( and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St, Baltimore, MD 21211, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](